Keeping Clinical Trials Going During a Pandemic

RARECast - A podcast by RARECast - Thursdays

Categories:

When the COVID-19 pandemic hit, it disrupted all aspects of daily life. Many drug developers were forced to suspend clinical trials because of the challenges of brining participants into medical centers with the risk of infection and the strain on healthcare workers. Palvella Therapeutics, which is developing an experimental therapy for a rare skin condition has been able to navigate the pandemic and continue its clinical study without disruption thanks to recognize the challenge early and adjusting its study plans accordingly. We spoke to Kathy Goin, vice president of development operations for Palvella Therapeutics, about its ongoing study, how it managed to continue unimpeded during the pandemic, and why she expects changes the company made will have a lasting effect on how it conducts clinical studies in the future.